**Pseudomonas aeruginosa** in Cancer Therapy: Current Knowledge, Challenges and Future Perspectives

Zheng Pang*, Meng-Di Gu and Tong Tang*

1 Innovative Institute of Chinese Medicine and Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China,
2 School of Art & Design, Qilu University of Technology (Shandong Academy of Sciences), Jinan, China

Drug resistance, undesirable toxicity and lack of selectivity are the major challenges of conventional cancer therapies, which cause poor clinical outcomes and high mortality in many cancer patients. Development of alternative cancer therapeutics are highly required for the patients who are resistant to the conventional cancer therapies, including radiotherapy and chemotherapy. The success of a new cancer therapy depends on its high specificity to cancer cells and low toxicity to normal cells. Utilization of bacteria has emerged as a promising strategy for cancer treatment. Attenuated or genetically modified bacteria were used to inhibit tumor growth, modulate host immunity, or deliver anti-tumor agents. The bacteria-derived immunotoxins were capable of destructing tumors with high specificity. These bacteria-based strategies for cancer treatment have shown potent anti-tumor effects both in vivo and in vitro, and some of them have proceeded to clinical trials. *Pseudomonas aeruginosa*, a Gram-negative bacterial pathogen, is one of the common bacteria used in development of bacteria-based cancer therapy, particularly known for the *Pseudomonas* exotoxin A-based immunotoxins, which have shown remarkable anti-tumor efficacy and specificity. This review concisely summarizes the current knowledge regarding the utilization of *P. aeruginosa* in cancer treatment, and discusses the challenges and future perspectives of the *P. aeruginosa*-based therapeutic strategies.

**Keywords:** *Pseudomonas aeruginosa*, cancer therapy, anti-cancer agent, vector, immunotoxin

**INTRODUCTION**

Cancer is one of the most dreaded diseases of human, and is the first or second leading cause of death in most countries of the world (1). The hallmark of cancer includes uncontrolled proliferation, resistance to cell death, insensitivity to growth suppressors, sustained angiogenesis, replicative immortality, and abilities of invasion and metastasis (2). The conventional treatment of cancer includes surgery, radiotherapy and chemotherapy, which are well-established and effective in...
eliminating fast-growing cancer cells (3). However, these conventional cancer therapies have a lot of limitations, including inefficacy in drug-resistant tumors, lack of tumor specificity, undesirable cytotoxicity to normal cells and adverse effects on cancer patients (4). In the past decade, alternative and complementary cancer therapies including nanoparticles, extracellular vesicles for delivering therapeutic agents, gene therapy, targeted therapy, diet therapy, herbal medicine, bacteriotherapy and magnetic hyperthermia have gained a high degree of research attention, and exhibited excellent anti-tumor effects in vitro and in animal models (5, 6). However, most of the therapeutic approaches are currently under preclinical and clinical investigation.

Bacteria-mediated cancer therapy has emerged as a promising approach in cancer treatment, which is capable of overcoming some of the limitations of conventional cancer therapies (7). Many obligate or facultative anaerobic bacterial species including Clostridium sp., Bifidobacterium sp., Salmonella sp., Bacillus sp., Escherichia coli, Listeria monocytogenes and Pseudomonas aeruginosa have been reported to penetrate and replicate in the hypoxic regions of tumors or accumulate in the tumor microenvironment (8, 9). Furthermore, these therapeutic bacteria are able to inhibit tumor growth and metastasis by production of toxins and stimulation of host immune responses (10). In addition, bacteria can be genetically engineered for their accessible genes, and used as vectors to deliver anti-tumor agents or immunomodulatory proteins to tumor sites (11, 12). Importantly, the genetically modified, live attenuated bacteria can be eliminated by antibiotics or triggering and strengthening host immune responses by immunomodulators such as cytokines and host defense peptides after the cancer treatment to prevent unintended infections (13–15).

Pseudomonas aeruginosa is a Gram-negative, aerobic bacteria that is harmless to healthy individuals but causes severe infections in cystic fibrosis patients and immunocompromised individuals (16). Although P. aeruginosa is categorized as an aerobe, it acts as a facultative anaerobe capable of using alternative electron acceptors such as nitrate (NO₃⁻), nitrite (NO₂⁻) and nitrous oxide (N₂O) to produce energy under oxygen-limited conditions (17). Live attenuated, inactivated or genetically modified P. aeruginosa have been reported to effectively cause tumor regression in mouse models by inducing cancer cells to undergo programmed cancer cell death (18–21), dampening proliferative signaling (22–24), and activating host anti-tumor responses (25, 26). Furthermore, many P. aeruginosa virulence factors including exotoxin A (ExoA), exoenzyme T (ExoT), azurin, cyclopeptides, Pacaspase recruitment domain (Pa-CARD) and rhamnolipids have been found to exert potent cytotoxicity against various cancer cells (27–32). In particular, ExoA is the most toxic virulence factor of P. aeruginosa, and widely applied in construction of immunotoxins for targeted cancer therapy (33). The present review aimed to concisely summarize and discuss the current findings on P. aeruginosa-based cancer therapeutic approaches, including live attenuated or inactivated P. aeruginosa as anti-cancer agents, P. aeruginosa as vaccine vectors for tumor antigen delivery, and P. aeruginosa ExoA-based immunotoxins (Figure 1).

**LIVE ATTENUATED OR INACTIVATED P. AERUGINOSA AS ANTI-CANCER AGENTS**

The role of bacteria as anti-cancer agents was first identified by German physicians W. Busch and F. Fehleisen who observed tumor regression in the cancer patients suffered from erysipelas caused by Streptococcus pyogenes infection (34). In 1891, William Coley, an American surgeon, inoculated cancer patients with S. pyogenes, which was the first time that bacteria were used to treat cancer (35). Hypoxia is a common feature of solid tumors, which is characterized by insufficient oxygen supply caused by rapid tumor growth. (36). Moreover, the hypoxic tumor microenvironment promotes tumor growth and angiogenesis (37). A number of obligate anaerobes including Clostridium sp. and Bifidobacterium sp. and facultative anaerobes including Salmonella sp., Bacillus sp., E. coli, L. monocytogenes and P. aeruginosa have been reported to colonize and replicate in the hypoxic region of tumors (10). Of note, the bacteria used in cancer treatment are required to be attenuated or genetically modified to reduce their toxicity and the ability to replicate before applying in treatment.

Pseudomonas aeruginosa-mannose sensitive hemagglutinin (PA-MSHA) is a genetically engineered P. aeruginosa strain characterized by high expression of mannose-sensitive hemagglutination (MSHA) fimbriae on its surface, which lowers toxicity by minimizing the exposure of other surface virulence factors such as LPS and flagella (38). Moreover, the MSHA fimbriae has been recognized as a novel ligand of Toll-like receptor 4 (TLR4) (39). Previous studies have shown that PA-MSHA suppressed tumor progression by induction of apoptosis through activating caspase-3, -8 or -9 (18, 19, 40), inhibition of cancer proliferative signaling such as EGFR, NRF2/KEAP1 and hedgehog signaling (22–24), and modulation of host immune responses through enhancing T cell responses, dendritic cell (DC) maturation and M1 macrophage polarization (25, 26, 41). Generally, the live or inactivated PA-MSHA was administered by subcutaneous injection in clinical trials or mouse models, which enhanced host anti-tumor immune responses systemically (19, 26, 42, 43). Moreover, the live PA-MSHA may enter the tumor tissues from blood circulation via passive entrapment in the leaky tumor vasculature or chemotaxis toward the chemicals released by the dying tumor tissue (44, 45). The heat-inactivated PA-MSHA combined with chemotherapy has been applied in clinical trials for treatment of breast cancer, lung cancer and lymphoma in China (42, 43, 46, 47). Most of the clinical studies suggested that the combination of inactivated PA-MSHA and chemotherapy drugs could improve the clinical efficacy of chemotherapy without increasing toxicity to cancer patients. Furthermore, the patients who were more responsive to PA-MSHA stimulation may receive better treatment outcomes.
Lv et al. carried out a phase II clinical trial of inactivated PA-MSHA combined with capecitabine for treatment of HER2-negative metastatic breast cancer, and found that the patients with moderate immune-related adverse events (IRAEs) such as fever or skin induration caused by PA-MSHA injection manifested higher survival (25.4 months vs. 16.4 months) and longer progression-free survival (8.2 months vs. 3.1 months) compared to the patients who had no or mild IRAEs (43). One of the challenges for *P. aeruginosa*-based cancer treatment is that *P. aeruginosa* is able to induce a self-degradative and recycling process termed autophagy (48–50), which increases the resistance of cancer cells to chemotherapy and radiotherapy (51, 52). Xu et al. identified that PA-MSHA induced autophagy in human breast cancer cells through upregulation of the endoplasmic reticulum (ER) stress-activated IRE1 signaling, and treatment of an autophagy inhibitor 3-methyladenosine (3-MA) enhanced the PA-MSHA-induced apoptosis of breast cancer cells in vitro and tumor regression in vivo (53). This study suggests that inhibition of autophagy can increase the effectiveness of *P. aeruginosa*-induced tumor regression.

In addition to PA-MSHA, the anti-tumor effects of a clinical isolate of *P. aeruginosa* strain 1409 were examined in vitro and in vivo by Qi et al. (20). The authors demonstrated that *P. aeruginosa* 1409 induced a programmed necrosis (necroptosis) of TC-1 tumor cells through activation of TLR4-RIP3-MLKL, and the HMGB1 released by the dying tumor cells further induced DC maturation and migration to tumor sites. Subsequently, the mature DC promoted T-cell responses by presenting tumor-associated antigens, thus resulting in remarkable tumor suppression in a TC-1 grafted tumor mouse model (20). This study indicates that the pathogenic clinical strains of *P. aeruginosa* could induce a potent anti-tumor response by reshaping tumor microenvironment. However, the live pathogenic *P. aeruginosa* strains must be attenuated or modified to reduce toxicity prior to clinical use due to the weakened immune system of cancer patients, which increases the prevalence of *P. aeruginosa* infections (54). Furthermore, this bacterial pathogen is resistant to many of the currently available antibiotics such as aminoglycosides, quinolones and β-lactams (55). Thus, clearance of the pathogenic *P. aeruginosa* strains after treatment is more difficult compared to other therapeutic bacteria.

**PSEUDOMONAS AERUGINOSA AS VACCINE VECTORS FOR TUMOR ANTIGEN DELIVERY**

Many anaerobic bacteria are recognized as the attractive vectors for the delivery of therapeutic genes to tumors for their ability to internalize and replicate inside tumor cells or grow in the hypoxic tumor microenvironment (56). The therapeutic genes encode anti-tumor agents, cytotoxic peptides, therapeutic...
molecules or prodrug-converting enzymes (57). The ideal bacterial vectors would be administered systemically, and selectively deliver the therapeutic genes to tumor cells with less toxicity and immunogenicity. Once invading into tumors, the bacteria spread throughout the whole tumor tissues and produce therapeutic agents to inhibit tumor cells (12). Additionally, other than the therapeutic agents, some bacteria capable of surviving in antigen-presenting cells (APCs) or utilizing type III secretion system (T3SS) can be engineered as vaccine vectors that deliver tumor antigens to APCs and induce durable tumor-specific CD8+ T cell responses (58, 59). To date, many bacterial species including Clostridium sporogenes, Salmonella typhimurium, Bifidobacterium longum, E. coli, L. monocytogenes and P. aeruginosa have been genetically modified as vectors for delivery of tumoricidal agents, immunomodulatory proteins or tumor antigens, which showed success in a variety of animal tumor models (60–65).

Gram-negative bacteria utilize T3SS to inject bacterial effectors into host cell cytoplasm (66). In the past decade, the delivery tools based on bacterial T3SS have attracted a lot of research attentions for development of therapeutic cancer vaccines (67). A French research group genetically modified the live attenuated P. aeruginosa strains as vaccine vectors that directly deliver tumor antigens to APCs via T3SS injection and trigger antigen-specific CD8+ T cell responses systemically, leading to long-lasting anti-tumor immune responses (59, 60, 68, 69). For instance, Epaulard et al. generated an attenuated P. aeruginosa strain CHA-OST S54-Ova with deletion of two T3SS toxins, exoenzyme S (ExoS) and ExoT, which were able to induce apoptosis, block production of reactive oxygen species and inhibit the phagocytic activity of host cells (70–73), and this P. aeruginosa strain was genetically modified to express a fusion gene encoding the N-terminal 54 amino acids of ExoS for T3SS-mediated translocation and the C-terminus of ovalbumin (OVA) for immunogenicity (60). Furthermore, the strain CHA-OST S54-Ova was able to elevate the number of OVA-specific CD8+ T cells in vivo, and the mice inoculated with CHA-OST S54-Ova were resistant to the challenge of OVA-expressing mouse melanoma cell line B16 (60). In a separated study, the authors developed another P. aeruginosa strain CHA-OAL by deleting four virulence genes, including exoS, exoT, aroA and lasI, which displayed reduced toxicity and enhanced efficiency for delivering tumor antigens (74). The P. aeruginosa aroA gene encodes an enzyme called 5-enolpyruvylshikimate 3-phosphate synthase, which is essential for synthesis of aromatic amino acids, and deletion of this gene was found to promote the intracellular growth of P. aeruginosa and elicit an increased level of opsonic antibodies in host against P. aeruginosa (75, 76). LasI is an acyl-homoserine lactone synthase that catalyzes the synthesis of N-(3-oxododecanoyl)-L-homoserine lactone (3O-C12-HSL), a quorum sensing signal molecule critical for regulating expression of many P. aeruginosa virulence factors, including ExoA, LasA protease, LasB elastase and alkaline protease (77, 78). Derouazi et al. engineered the P. aeruginosa CHA-OST to express a fusion protein comprising of the N-terminal 54 amino acids of ExoS and a tumor antigen TRP2 epitope, and identified that the TRP2 epitope (125-376) could activate the TRP2-specific CD8+ T cell response, leading to a significant protection of mice against glioma (69). In addition, a killed but metabolically active (KBMA) P. aeruginosa strain OSTAB was created by deletion of ExoS, ExoT and the two subunits of the exonuclease UvrABC, UvrA and UvrB, important for bacterial nucleotide excision repair, and it was subsequently photo-inactivated (79). This KBMA P. aeruginosa strain was incapable of replicating in host but still immunologically active with functional T3SS, which has been suggested to be a promising and safe antigen delivery vector for anti-tumor immunotherapy (68).

**P. AERUGINOSA EXOA-BASED IMMUNOTOXINS FOR CANCER TREATMENT**

Bacterial toxins in cancer therapy have been extensively studied in the past decade, which effectively change the cellular functions and processes by influencing cell proliferation, differentiation and apoptosis, and eventually kill the tumor cells (57). The theory behinds the bacterial toxin-mediated cancer therapy is creation of chimeric proteins consisting of the catalytic part of a toxin responsible for killing tumor cells and a receptor-binding part such as an antibody or a receptor ligand for specific tumor targeting, and these chimeric proteins are termed as immunotoxins (80). Monoclonal antibodies are commonly used in generation of the tumor cell binding parts in immunotoxin, which bind to the specific molecules that are highly expressed on tumor cell membrane. Upon binding to the target molecules, the immunotoxins are endocytosed and released to host cytosol, ultimately inducing toxin-mediated cell death (81). Moreover, the antigen-binding domain of the antibody part in immunotoxins is usually shortened or modified to reduce immunogenicity (80). The most commonly used bacterial toxins for generation of immunotoxins include Diphtheria toxin and Pseudomonas exotoxin A (PE), which have showed great anti-tumor efficiency both in vivo and in vitro, and some of them are currently under clinical investigation (82, 83).

PE is the most toxic virulence factor in P. aeruginosa which inhibits protein synthesis through ADP-ribosylation of eukaryotic elongation factor 2 (84). It is a single polypeptide chain that can be divided into three functional domains, including receptor binding domain (I), translocation domain (II) and catalytic domain (III) (85). Moreover, the binding of PE receptor binding domain to the low density lipoprotein receptor related protein (LRP1), also known as CD91, on host cell surface mediates uptake of PE via receptor-mediated endocytosis (84). The PE-based immunotoxins were generated by replacing the PE receptor binding domain with the variable fragment (Fv) of a monoclonal antibody or a receptor ligand such as a growth factor or a cytokine, which targets a tumor-specific antigen or a receptor molecule overexpressed on tumor cell surface (86).
| Immunotoxin names | Toxin part | Receptor-binding part | Target | Research type | Reference |
|------------------|------------|-----------------------|--------|---------------|-----------|
| HN3-ABD-T20      | Truncated PE lacking domain II attached to ABD | Anti-GPC3 (HN3 nanobody) | Hepatocellular carcinoma cells | In vitro and in vivo | (87) |
| D7(VL-VH)-PE40    | PE40       | Anti-PSMA scFv         | Prostate cancer cells | In vitro and in vivo | (88) |
| NZ-1-(scdsFv)-PE38KDEL | PE38KDEL | Anti-podoplanin (NZ-1) scdsFv | Malignant brain tumor cells | In vitro and in vivo | (89) |
| dhuVH6-PE38      | PE38       | CD7 nanobody          | T-cell acute lymphoblastic leukemia | In vitro and in vivo | (90) |
| 2E4-PE38         | PE38       | Anti-CD25 scFv        | Regulatory T cells | In vivo | (91) |
| HM1.24-ETA'      | ETA'       | Anti-CD317 scFv       | Myeloma cells | In vitro and in vivo | (92) |
| scFv13-ETA'      | ETA'       | Anti-CD13 scFv        | Various cancer cells | In vitro | (93) |
| CPE-ETA'         | ETA'       | Claudin-4-binding domain of Clostridium perfringens enterotoxin | Various cancer cells | In vitro | (94) |
| D2C7-(scdsFv)-PE38KDEL | PE38KDEL | Anti-EGFR scdsFv | Glioblastoma | Phase I/II clinical trial | (95) |
| DARPin-LoPE      | LoPE (Truncated PE lacking domain I, II and B cell epitopes) | HER2-specific DARPin | Ovarian cancer cells | In vitro and in vivo | (96) |
| EGF-PE40         | PE40       | EGF                   | Bladder cancer cells | In vitro | (97) |
| EGF-PE40, EGF-PE24mut | mPE24 | Anti-CD89 scFv | Myeloid leukemia cells | In vitro | (98) |
| HER2-PE24        | PE24       | Anti-Her2 scFv        | HER2-expressing breast cancer cells | In vitro | (99) |
| HER2-PE25-X7     | PE25       | HER2-specific affibody molecule (ZHER2:2891) | HER2-expressing cancer cells | In vitro and in vivo | (100) |
| ADAPT6-ABD-PE25  | PE25       | ADAPT6                | HER2-expressing breast cancer cells | In vitro | (101) |
| IL-4-PE          | PE38KDEL   | IL-4                  | Ovarian cancer cells | In vitro and in vivo | (102) |
| MSH-PE38KDEL     | PE38KDEL   | Melanophore-stimulating hormone | Melanoma cells | In vitro and in vivo | (103) |
| SS1(dsFv)PE38    | PE38       | Anti-mesothelin scFv  | Mesothelioma | Phase I clinical trial | (104) |
| J591scFvPE38QQR  | PE38QQR    | Anti-PSMA (J591) scFv | Prostate cancer cells | In vitro and in vivo | (105) |
| D7(VL-VH)-PE40   | PE40       | Anti-PSMA (D7) scFv   | Prostate cancer cells | In vitro | (106) |
| BPC-Neu5Ac-Dimer-LL-ETA-RDEL | ETA' | Synthetic sialosides (GPC-Neu5Ac-dimers) | CD22-positive B-cell lymphoma cells | In vitro | (107) |
| VGRNb-Pe-PE      | PE38       | VEGFR2-specific Nanobody (3VGFR19) | VEGFR2-expressing cancer cells | In vitro | (108) |
| hGC33–PE38       | PE38       | Anti-GPC3 (hGC33) scFv | Small cell lung cancer cells | In vitro | (109) |
| MOC31PE         | PE         | Anti-EpCAM (MOC31) scFv | Peritoneal surface malignancies | In vitro and in vivo | (110) |
| 806-PE38         | PE38       | Anti-EGFR (m806) antibody scFv | Triple-negative breast cancer cells | In vitro and in vivo | (111) |
| scFv2A9-PE       | PE38KDEL   | Anti-EpCAM scFv       | EpCAM-positive human | In vitro | (112) |
| HN3-PE38         | PE38       | Anti-GPC3 (HN3) scFv  | Hepatocellular carcinoma cells | In vitro and in vivo | (113) |
| LMB-12           | PE domain III | Anti-mesothelin scFv | Colorectal cancer cells | In vitro and in vivo | (114) |
| LMB-100          | PE24       | Anti-mesothelin Fab    | Hepatocellular carcinoma cells | In vitro and in vivo | (115) |
| LMB-164          | PE domain III attached to ABD | Anti-mesothelin scFv | Hepatocellular carcinoma cells | In vitro and in vivo | (116) |
| GD9P             | PE38       | GD9                   | Colorectal cancer cells | In vitro and in vivo | (117) |
| TGFα-PE38        | PE38       | TGFα                  | CCK2R-expressing colorectal cancer cells | In vitro and in vivo | (118) |
| T22-PE24-H6      | PE24       | T22 (CXCR4 ligand)    | Various cancer cells | In vitro and in vivo | (119) |
The representative PE-based immunotoxins discovered and evaluated in the past decade for cancer treatment were summarized in Table 1.

The naming of the truncated PE used in construction of the recombinant immunotoxins is usually based on their molecular weight. PE38 and PE40, two truncated forms of PE (38 kDa and 40 kDa, respectively), are most commonly used for immunotoxin construction, and both of them lack the receptor-binding domain (I) (119). Furthermore, as a foreign protein, the immunogenicity of immunotoxins is able to induce production of anti-drug antibodies in host, which neutralize and decrease the efficiency of the immunotoxins (82). Alteration of immunotoxin structure is a feasible strategy to reduce immunogenicity (120). Previous studies have reported that removal of the B cell or T cell epitopes from the PE-based immunotoxins could significantly reduce the immunogenicity and enhanced the anti-tumor efficiency both in vitro and in vivo (121–124). The B cell epitopes in PE38 were mapped by measuring the reactivity of PE38 to the monoclonal antibodies isolated from the mice or patients treated with the PE38-based immunotoxins (125), and they were removed by point mutations of the large hydrophilic amino acids such as arginine, glutamine, glutamic acid and lysine to alanine, serine or glycine, which prevents PE38 from binding to the B cell antigen receptors (124). The T cell epitopes were identified by incubating human peripheral blood mononuclear cells (PBMCs) or mouse splenocytes with whole PE38, and the reacting T-cells were subsequently stimulated with various PE38 peptides (122). Furthermore, the peptides capable of triggering T cell response were determined to contain the T cell epitopes, and the removal of T cell epitopes in PE38 could be achieved by deletion or point mutations (120). To date, many PE-based immunotoxins have been applied in clinical treatment of B-cell lymphoma (126), ovarian cancer (127), mesothelioma (105), breast cancer (128), esophageal cancer (128), brain cancer (95, 129, 130), and pancreatic adenocarcinoma (131). However, most of them are still in the early stage (phase I or II) of clinical trials, and the preliminary data indicated that toxicity and limited efficacy were the major challenges. In addition, the synergistic antitumor activity of PE-based immunotoxins combined with chemotherapeutic agents has been observed in vitro and in mouse tumor models (132–134). However, the combination of PE-based immunotoxins and chemotherapy lacks the clinical evidence for safe use in cancer patients. Alewine et al. demonstrated that the combination of immunotoxin LMB-100 and nab-paclitaxel could amplify the toxic side effects of LMB-100 (131).

CONCLUSION AND FUTURE PERSPECTIVES

Tumor resistance to the conventional cancer therapies such as radiotherapy and chemotherapy is major cause of cancer relapse, and has led to a significant barrier in cancer treatment. The bacteria-based cancer therapy has emerged as a promising alternative or complementary strategy for cancer treatment, which exhibited great anti-tumor effects both in vitro and in animal tumor models. Among the therapeutic bacteria, P. aeruginosa takes advantages of large accessible genome, production of virulence factors with potent anti-tumor activities, and expression of various immunogenic molecules on membrane. The peritrichous P. aeruginosa strain PA-MSHA with MSHA fimbiae and low toxicity has been directly used as a therapeutic agent to destroy tumors by inducing tumor cell apoptosis, inhibiting tumor growth, and activating host immune responses. Moreover, the inactivated PA-MSHA combined with chemotherapy has proceeded to clinical trials. However, the PA-MSAH treatment seems to be ineffective to the patients who were tolerant to PA-MSHA stimulation. Therefore, a pre-test of the tolerance to PA-MSHA on cancer patients is recommended, and the patients with moderate adverse reactions will be proceeded for further treatment. The genetically engineered P. aeruginosa strain is able to activate tumor-specific CD8+ T cells by delivering tumor antigens to DCs, inducing long-lasting anti-tumor immunity. Moreover, for safety concern, the live attenuated P. aeruginosa strains should be unable to replicate, and are easily eliminated after treatment. PE is the most widely used P. aeruginosa toxin for construction of recombinant immunotoxins. Although the PE-based immunotoxins have shown significant in vitro and in vivo anti-tumor effects on nearly all types of tumors. However, only a few of them has proceeded to clinical practice, and the low efficiency and unanticipated toxicity to patients remain a big challenge that must be overcome in clinical applications. In future, development of new PE-based immunotoxins with high specificity and less immunogenicity should be one of the major tasks in bacteria-based cancer therapy, which is challenging but rewarding. Overall, the P. aeruginosa-based cancer therapies are promising strategies for cancer treatment, and they are particularly more effective in combination with conventional cancer therapies.

AUTHOR CONTRIBUTIONS

ZP contributed to the conceptualization, manuscript writing, supervision and funding acquisition. M-DG contributed to manuscript writing. TT made the figures and edited the manuscript. All the authors read and approved the final manuscript.

FUNDING

This study was funded by the National Natural Science Foundation of China (Grant No. 82002112).

ACKNOWLEDGMENTS

The figures in this study were created with BioRender.com.
REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71:209–49. doi: 10.3322/caac.21660

2. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell (2011) 144:646–74. doi: 10.1016/j.cell.2011.02.013

3. Arai H. Regulation and Function of Versatile Aerobic and Anaerobic Respiratory Metabolism in Pseudomonas Aeruginosa. J Microbiol (2012) 6:ed16. doi: 10.3332/jmc.2012.

4. Cao Z, Shi L, Li Y, Wang J, Wang D, Wang G, et al. Pseudomonas Mannose-Sensitive Hemagglutinin Inhibits the Growth of Doxorubicin-Resistant MCF-7/ADR Human Breast Cancer Cells by Downregulating Nrf2/p62. Cancer Med (2016) 5:3520–31. doi: 10.1002/cam4.938

5. Chang L, Xiao W, Yang Y, Li H, Xia D, Yu G, et al. Pseudomonas aeruginosa Mediated Necrosis in Mouse Tumor Cells Induces Long-Lasting Systemic Antitumor Immunity. Front Oncol (2020) 10:610651. doi: 10.3389/fonc.2020.610651

6. Wang M, Zhao J, Zhang L, Wang L, Lin W, Yang M, et al. Pseudomonas aeruginosa ManD Promotes T-Cell Response via Toll-Like Receptor 4-Mediated Dendritic Cells to Slow Tumor Progression in Mice. J Pharmacol Exp Ther (2014) 349:279–87. doi: 10.1124/jpet.113.212316

7. Bernardes N, Ribeiro AS, Abreu S, Vieira AF, Carreto L, Santos M, et al. High-Throughput Molecular Profiling of a P-Cadherin Overexpressing Breast Cancer Cell Line Reveals New Targets for the Anti-Cancer Bacterial Protein Azurin. Int J Biochem Cell Biol (2014) 50:1–9. doi: 10.1016/j.biocel.2014.01.023

8. Rahimi K, Lotfabad TB, Jabeen F, Mohammad Ganji S. Cytotoxic Effects of Mono- and Di-Rhamnolipids From Pseudomonas Aeruginosa MR01 on MCF-7 Human Breast Cancer Cells. Colloids Surf B Biointerfaces (2016) 144:646–51. doi: 10.1016/j.colsurfb.2016.01.002

9. Vazquez-Rivera D, Gonzalez O, Guzman-Rodriguez J, Diaz-Perez AL, Esparvarinha M, et al. The Role of Hypoxia in the Tumor Microenvironment in Tumorigenesis. J Cancer (2017) 8:761. doi: 10.1159/2015.197608

10. Coley WB. The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas. With a Report of Ten Original Cases. 262:1893.

11. Kwan JM, Fialho AM, Kundu M, Thomas J, Hong CS, Das Gupta TK, et al. Bacterial Proteins as Potential Drugs in the Treatment of Leukemia. Leuk Res (2009) 33:1392–9. doi: 10.1016/j.leukres.2009.01.024

12. Faure E, Kwong K, Nguyen D. Pseudomonas Aeruginosa in Chronic Lung Infections: How to Adapt Within the Host? Front Immunol (2018) 9:2416.

13. Marceau V, Chevrette J, Signoret D, Rainville L, LeBlanc J, et al. Pseudomonas Aeruginosa: Mannose-Sensitive Hemagglutinin Inhibits the Growth of Human Hepatocarcinoma Cells via Mannose-Mediated Apoptosis. Dig Dis Sci (2009) 54:2118–27. doi: 10.1007/s10620-008-0603-5

14. Chang L, Xiao W, Yang Y, Li H, Xia D, Yu G, et al. Pseudomonas aeruginosa-Mannose-Sensitive Hemagglutinin Inhibits Epidermal Growth Factor Receptor Signaling Pathway Activation and Induces Apoptosis in Bladder Cancer Cells. In Vitro and In Vivo. Urol Oncol (2014) 32:6:11–38. doi: 10.1016/j.juroleon.2013.02.013

15. Qi H, He JR, Jin SM, Yang X, Bai HM, Liu CB, et al. P. Aeruginosa Mediated Necrosis in Mouse Tumor Cells Induces Long-Lasting Systemic Antitumor Immunity. Front Oncol (2020) 10:610651. doi: 10.3389/fonc.2020.610651

16. Mu XY. Success in Establishing the MSHA-Positive Pseudomonas Aeruginosa Fimbrial Strain. Wei Sheng Xu Xue Bao (1986) 26:176–9.
42. Chang J, Liu Y, Han B, Zhou C, Bai C, Li J. Pseudomonas Aeruginosa

41. Miao ZF, Zhao TT, Miao F, Wang ZN, Xu YY, Mao XY, et al. The Mannose-Sensitive Hemagglutinin Pilus Strand of Pseudomonas Aeruginosa Shift Peritoneal Milky Spot Macrophages Towards an M1 Phenotype to Dampen Peritoneal Dissemination. Tumour Biol (2014) 35:2485–93. doi: 10.1007/s13277-013-1559-4

40. Liu J, Duan X. PA-MSHA Induces Apoptosis and Suppresses Metastasis by Tumor Associated Macrophages in Bladder Cancer Cells. Cancer Cell Int (2017) 17:76. doi: 10.1186/s12935-017-0445-3

39. Mossman KL, Mian MF, Lauron NM, Gyles CL, Lichte B, Mackenzie R, et al. Cutting Edge: Fish-H Adhesin of Type I Fimbriae is a Novel TLRA Ligand. J Immunol (2008) 181:6172–6. doi: 10.4049/jimmunol.181.10.6702

38. Baban CK, Cronin M, O’Hanlon D, O’Sullivan GC, Tangney M. Bacteria as Vectors for Gene Therapy of Cancer. J Immunol (2012) 35:223–34. doi: 10.1186/1471-2407-14-273

37. Patyar S, Joshi R, Byvar DS, Prakash A, Medhi B, Das BK. Bacteria in Cancer Therapy: A Novel Experimental Strategy. J BioMed Sci (2010) 17:21. doi: 10.1186/1423-0127-17-21

36. Epaulard O, Toussaint B, Quenee L, Derouazi M, Roso N, Villiers C, et al. Anti-Tumor Immunotherapy via Antigen Delivery From a Live Attenuated Genetically Engineered Pseudomonas Aeruginosa Type III Secretion System-Based Vector. Mol Ther (2006) 14:656–61. doi: 10.1016/j.ymthe.2006.06.011

35. Lee J, Shin JH, Shim HS, Lee CY, Kim DJ, Kim YS, et al. Autophagy During Pseudomonas Aeruginosa Infection. Biosci Rep (2014) 34:116. doi: 10.1042/BSHR20140015

34. Pang Z, Xu Y, Zhu Q. Early Growth Response 1 Suppresses Macrophage Phagocytosis by Inhibiting NFR2 Activation Through Upregulation of Autophagy During Pseudomonas Aeruginosa Infection. Front Cell Infect Microbiol (2021) 11:773665. doi: 10.3389/fcimb.2021.773665

33. Yuan K, Huang H, Liu F, Chen Y, Tang S, Li, et al. Optimal Epitope Composition After Antigen Screening Using a Live Bacterial Delivery Vector: Application to TRP-2. Bioeng Bugs (2010) 1:51–60. doi: 10.4161/bbug.1.1.9482

32. Cowell BA, Chen DY, Frank DW, Valls AJ, Fleiszig SM. ExoT of Cytotoxic Pseudomonas Aeruginosa Prevents Uptake by Corneal Epithelial Cells. Infect Immun (2012) 80:3935–43. doi: 10.1128/IAI.00860-12

31. Wang Y, Gouellec AL, Chaker H, Asrih H, Polack B, Toussaint B. Optimization of Antitumor Immunotherapy Mediated by Type III Secretion System-Based Live Attenuated Bacterial Vectors. J Immunother (2012) 35:223–34. doi: 10.1016/j.jimmunol.181.10.6702

30. Derouazi M, Wang Y, Marlu R, Epaulard O, Mayol JF, Pasqual N, et al. Optimal Epitope Composition After Antigen Screening Using a Live Bacterial Delivery Vector: Application to TRP-2. Bioeng Bugs (2010) 1:51–60. doi: 10.4161/bbug.1.1.9482

29. Vareechon C, Zmina SE, Karmakar M, Pearlman E, Rietsch A. Pseudomonas Aeruginosa Mutant of Pseudomonas Aeruginosa as a Candidate Intranasal Vaccine. Infect Immun (2013) 8:4546–51. doi: 10.1128/IAI.00895-13

28. Paterson Y, Guirnala PD, Wood LM. Listeria and Salmonella Bacterial Vectors of Tumor-Associated Antigens for Cancer Immunotherapy. Semin Immunol (2010) 22:183–9. doi: 10.1016/j.smim.2010.02.002
Pseudomonas aeruginosa

95. Chandramohan V, Pegram CN, Piao H, Szafranski SE, Kuan CT, Pastan IH, Hashimi SM, Yu S, Alqurashi N, Ipe DS, Wei MQ. Immunotoxin-Mediated Grieger E, Gresch G, Niesen J, Woitok M, Barth S, Fischer R, et al. Ef 93. Ma Z, Tan I. Immunogenicity of Immunotoxins Containing 78. Lee J, Zhang L. The Hierarchy Quorum Sensing Network in Pseudomonas 79. Le Gouellec A, Chauchet X, Laurin D, Aspord C, Verove J, Wang Y, et al. A 82. Mazor R, Pastan I. Immunogenicity of Immunotoxins Containing 88. Michalska M, Schultze-Seemann S, Bogatyreva L, Hauschke D, Wetterauer 83. Sha 87. Fleming BD, Urban DJ, Hall MD, Longerich T, Greten TF, Pastan I, et al. Recombinant Anti-Podoplanin (NZ-1) Immunotoxin for the 100. Lee S, Park S, Nguyen MT, Lee E, Kim J, Baek S, et al. A Chemical Conjugate Between HER2-Targeting Antibody Fragment and Pseudomonas Exotoxin A Fragment Demonstrates Cytotoxic Effects on HER2-Expressing Breast Cancer Cells. 109. Baiz D, Hassan S, Choi YA, Flores A, Karpova Y, Yancey D, et al. Ba 108. Schweizer A, Wohner M, Prescher H, Brossmer R, Nitschke L. Targeting of 107. Noll T, Schultze-Seemann S, Kuckuck I, Michalska M, Wolf P. Synergistic 106. Baiz D, Hassan S, Choi YA, Flores A, Karpova Y, Yancey D, et al. 105. Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, et al. Phase 1 104. Baiz D, Hassan S, Choi YA, Flores A, Karpova Y, Yancey D, et al. 103. 84. Michalska M, Wolf P. Pseudomonas Exotoxin A: Optimized by Evolution 86. Song J, Zhang L, Song Y, Zhang X, Liu R, Zhang X, et al. The tyrosine 81. Kim J, Lim SH, Jang J, Kim H, Lee H, Kim WJ, et al. A Prostate Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple- 102. Schweizer A, Wohner M, Prescher H, Brossmer R, Nitschke L. Targeting of 101. Gao F, Xiong H, Feng D, Wang Z, Zhan Y, Zhang Y, et al. A Novel Immunotoxin Targeting Claudin-4 Inhibits the Proliferation of Cancer Cells. 107. Noll T, Schultze-Seemann S, Kuckuck I, Michalska M, Wolf P. Synergistic 100. Lee S, Park S, Nguyen MT, Lee E, Kim J, Baek S, et al. A Chemical Conjugate Between HER2-Targeting Antibody Fragment and Pseudomonas Exotoxin A Fragment Demonstrates Cytotoxic Effects on HER2-Expressing Breast Cancer Cells. 106. Baiz D, Hassan S, Choi YA, Flores A, Karpova Y, Yancey D, et al. Ba 108. Schweizer A, Wohner M, Prescher H, Brossmer R, Nitschke L. Targeting of 107. Noll T, Schultze-Seemann S, Kuckuck I, Michalska M, Wolf P. Synergistic 106. Baiz D, Hassan S, Choi YA, Flores A, Karpova Y, Yancey D, et al. Ba 105. Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, et al. Phase 1 104. Baiz D, Hassan S, Choi YA, Flores A, Karpova Y, Yancey D, et al. 103. 84. Michalska M, Wolf P. Pseudomonas Exotoxin A: Optimized by Evolution 86. Song J, Zhang L, Song Y, Zhang X, Liu R, Zhang X, et al. The tyrosine 81. Kim J, Lim SH, Jang J, Kim H, Lee H, Kim WJ, et al. A Prostate Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-
114. Gao W, Tang Z, Zhang YF, Feng M, Qian M, Dimitrov DS, et al. Immunotoxin Targeting Glypican-3 Regresses Liver Cancer via Dual Inhibition of Wnt Signalling and Protein Synthesis. Nat Commun (2015) 6:6536. doi: 10.1038/ncomms7536

115. Cerise A, Bera TK, Liu X, Wei J, Pastan I. Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer. Clin Colorectal Cancer (2019) 18:192–199.e191. doi: 10.1016/j.clcc.2019.06.006

116. Chang J, Liu X, Ren H, Lu S, Li M, Zhang S, et al. Pseudomonas Exotoxin A-Based Immunotherapy Targeting CCK2R-Expressing Colorectal Malignancies: An In Vitro and In Vivo Evaluation. Mol Pharm (2021) 18:2285–97. doi: 10.1021/acs.molpharmaceut.1c00095

117. Lim D, Kim KS, Kim H, Ko KC, Song JJ, Choi JH, et al. Anti-Tumor Activity of an Immunotoxin (TGFalpha-PE38) Delivered by Attenuated Salmonella Typhimurium. Oncotarget (2017) 8:37550–60. doi: 10.18632/oncotarget.17197

118. Falgas A, Pallares V, Serna N, Sanchez-Garcia L, Sierra J, Gallardo A, et al. Selective Delivery of T22-PE24-H6 to CXCR4(+) Diffuse Large B-Cell Lymphoma Cells Leads to Wide Therapeutic Index in a Disseminated Mouse Model. Theranostics (2020) 10:5169–80. doi: 10.7150/thno.45231

119. Havaei SM, Aucoin MG, Jahanian-Najafabadi A. Pseudomonas Exotoxin-Based Immunotoxins: Over Three Decades of Efforts on Targeting Cancer Cells With the Toxin. Front Oncol (2021) 11:781800. doi: 10.3389/fonc.2021.781800

120. Mazor R, King EM, Pastan I. Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins. Am J Pathol (2018) 188:1736–43. doi: 10.1016/j.ajpath.2018.04.016

121. Hu X, Zhang M, Zhang C, Long S, Wang W, Yin W, et al. Removal of B-Cell Epitopes for Decreasing Immunogenicity in Recombinant Immunotoxin Against B-Cell Malignancies. J BUON (2016) 21:1374–8.

122. Mazor R, Crown D, Addissie S, Jang Y, Kaplan G, Pastan I. Elimination of Murine and Human T-Cell Epitopes in Recombinant Immunotoxin Eliminates Neutralizing and Anti-Drug Antibodies In Vivo. J Cell Mol Immunol (2017) 14:432–42. doi: 10.1038/cmi.2015.91

123. Mazor R, Kaplan G, Park D, Jang Y, Lee F, Kreitman R, et al. Rational Design of Low Immunogenic Anti CD25 Recombinant Immunotoxin for T Cell Malignancies by Elimination of T Cell Epitopes in PE38. Cell Immunol (2017) 313:59–66. doi: 10.1016/j.cellimm.2017.01.003

124. Onda M, Beers R, Xiang L, Nagata S, Wang QC, Pastan I. An Immunotoxin With Greatly Reduced Immunogenicity by Identification and Removal of B Cell Epitopes. Proc Natl Acad Sci USA (2008) 105:11311–6. doi: 10.1073/pnas.0804851105

125. Onda M, Nagata S, FitzGerald DJ, Beers R, Fisher RJ, Vincent JJ, et al. Characterization of the B Cell Epitopes Associated With a Truncated Form of Pseudomonas Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients. J Immunol (2006) 177:8822–34. doi: 10.4049/jimmunol.177.12.8822

126. Kreitman R, Squires DR, Steter-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, et al. Phase I Trial of Recombinant Immunotoxin RF84 (dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies. J Clin Oncol (2005) 23:6719–29. doi: 10.1200/JCO.2005.11.437

127. Pai LH, Bookman MA, Ozols RF, Young RC, Smith JW, Longo DL, et al. Clinical Evaluation of Intraperitoneal Pseudomonas Exotoxin Immunonojugate OVB-PE in Patients With Ovarian Cancer. J Clin Oncol (1991) 9:2095–103. doi: 10.1200/JCO.1991.9.12.2095

128. Pai-Scherf LH, Villa J, Pearson D, Watson T, Liu E, Willingham MC, et al. Hepatotoxicity in Cancer Patients Receiving Erb-38, a Recombinant Immunotoxin That Targets the ErbB2 Receptor. Clin Cancer Res (1999) 5:2311–5.

129. Rainov NG, Heidecke V. Long Term Survival in a Patient With Recurrent Malignant Glioma Treated With Intratrathcal Infusion of an IL4-Targeted Toxin (NBI-3001). J Neurooncol (2004) 66:197–201. doi: 10.1023/B:NEON.0000013478.27640.1

130. Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, et al. Progress Report of a Phase I Study of the Intracerebral Microinfusion of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-Alpha and a Mutated Form of the Pseudomonas Exotoxin Termed PE-38 (TP-38) for the Treatment of Malignant Brain Tumors. J Neurooncol (2003) 65:27–35. doi: 10.1023/A:1026290315809

131. Alewine C, Ahmad M, Peer CJ, Hu ZI, Lee MJ, Yuno A, et al. Phase I/II Study of the Mesothelin-Targeted Immunotoxin LMB-100 With Nab-Paclitaxel for Patients With Advanced Pancreatic Adenocarcinoma. Clin Cancer Res (2020) 26:828–36. doi: 10.1158/1078-0432.CCR-19-2586

132. Kolyvas E, Rudloff M, Porouchynsky M, Landsman R, Hollevoet K, Venzon D, et al. Mesothelin-Targeted Immunotoxin RG7787 has Synergistic Anti-Tumor Activity When Combined With Taxanes. Oncotarget (2017) 8:9189–99. doi: 10.18632/oncotarget.13984

133. Liu XF, Xiang L, Zhou Q, Carralot JP, Prunotto M, Niederfellner G, et al. Actinomycin D Enhances Killing of Cancer Cells by Immunotoxin RG7787 Through Activation of the Extrinsic Pathway of Apoptosis. Proc Natl Acad Sci USA (2016) 113:10666–71. doi: 10.1073/pnas.1611481113

134. Singh R, Zhang Y, Pastan I, Kreitman RJ. Synergic Antitumor Activity of Anti-CD25 Recombinant Immunotoxin LMB-2 With Chemotherapy. Clin Cancer Res (2012) 18:1512–60. doi: 10.1158/1078-0432.CCR-11-1839

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Pang, Gu and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.